MedPal AI Plc

MedPal AI Plc

MPAL.L
MedPal AI PlcGB flagLondon Stock Exchange
3.85
GBp
+0.05
- -
29.92MMarket Cap
MedPal AI Plc
MPAL.L
(London Stock Exchange)

Recent

price

3.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
FRC
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
-0.02
Basic EPS, GAAP
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
Tangible Book Value per Share
413
413
413
175
Basic Weighted Avg Shares
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-4
Net Income, GAAP
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
1
Working Capital
- -
- -
- -
- -
LT Debt
- -
- -
- -
1
Total Equity
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-11,691.28%
Free Cash Flow
- -
- -
23,056.99%
Net Income, GAAP
- -
- -
29,353.98%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
-0.02
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
MedPal AI Plc operates as a technology-driven healthcare information company delivering AI-assisted medical data and decision-support solutions. The firm focuses on enabling clinicians, payers, researchers, and life sciences companies to access, analyze, and act on clinical and operational data through advanced analytics, machine learning models, and integrated platforms. Main Products and Services: AI-driven clinical decision support systems; AI-powered medical data platforms; natural language processing and transcription services for clinical documentation; population health analytics; risk stratification and predictive modeling; workflow automation and care-management solutions; data integration and interoperability tooling (HL7 FHIR interfaces, API access); data curation, normalization, and quality assurance; customizable dashboards and visualization tools; regulatory-compliant data governance and privacy solutions; secure cloud-hosted data repositories; professional services including implementation, integration, training, and ongoing support; healthcare reimbursement and coding analytics; research-grade data access for clinical trials and real-world evidence; software as a service subscriptions with tiered feature sets; on-premises deployment options for large-scale institutions; multi-tenant and single-tenant deployment models; security and compliance offerings (HIPAA, GDPR alignment, SOC 2). Latest Major Company Changes: Forms strategic alliances with healthcare providers and technology platforms to broaden data sources and deployment footprints; completes funding rounds supporting product expansion and regional market entries; launches new AI modules for real-time clinical risk scoring and patient engagement; expands geographic footprint into Europe and Asia-Pacific; undergoes branding or corporate reorganizations to reflect expanded capabilities; reports major operational scale improvements including added data centers and enhanced data security infrastructure within the last 1-2 years. Additional Context: Industry and segments include healthcare IT, health analytics, and AI-enabled clinical informatics; serves hospitals, health systems, private and public payers, pharmaceutical and life sciences firms, and research institutes; target customers include CIOs, CMIOs, clinical leaders, risk managers, and researchers; geographic operations span multiple regions including North America, Europe, and Asia-Pacific; founding year and headquarters location are part of the company profile; potential subsidiaries or parent relationships reflect corporate structure and group affiliations.